Press release
Novartis' Radioligand Therapies Pipeline and Strategic Acquisitions: Key Drivers Behind Radioligand Therapies Market Exponential Growth Through 2034 | DelveInsight
Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
DelveInsight's report, "Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 [https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides in-depth analysis of radioligand therapies market dynamics, epidemiology trends, and emerging technologies that will shape the future of radioligand therapies, which is transforming cancer treatment paradigms across multiple oncology indications.
Radioligand therapy works through a sophisticated mechanism that delivers targeted radiation directly to tumor sites. The process begins by identifying specific proteins overexpressed on cancer cell surfaces, then developing targeting molecules (ligands) attached to radioactive isotopes. These are administered intravenously and bind to target proteins on cancer cells, delivering localized radiation that damages the DNA of cancer cells while minimizing exposure to healthy tissues. Therapeutic radioisotopes are produced in special nuclear reactors or generators, then shipped to production facilities where they are bonded to cell-targeting compounds, creating ready-to-use therapies that can be administered in hospital or clinic settings.
The radioligand therapy landscape has seen substantial clinical progress since 2018, when the FDA approved LUTATHERA, manufactured by Novartis, as the first radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). LUTATHERA's success has been remarkable, with sales exceeding USD 450 million in the first nine months of 2023 alone, representing a 34% year-over-year growth.
Stay informed on the latest FDA approvals @ Radioligand Therapies FDA Approvals [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Novartis projects peak sales could surpass USD 1 billion as it expands into first-line therapy. In a significant milestone for pediatric oncology, LUTATHERA received FDA approval in 2024 as the first medicine specifically for pediatric patients with GEP-NETs, broadening its therapeutic reach to younger patient populations with these rare tumors.
The market's expansion accelerated in 2022 with the FDA's approval of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), also developed by Novartis (SWX: NOVN), for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. PLUVICTO demonstrated impressive commercial performance, generating approximately USD 980 million in sales during its first full year, narrowly missing blockbuster status.
Explore ongoing and upcoming clinical trials driving innovation in radioligand therapies @ Radioligand Therapies Clinical Trials [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Other established radioligand therapies include Bayer's XOFIGO (radium ra-223 dichloride) for castration-resistant prostate cancer with symptomatic bone metastases, and Spectrum Pharmaceuticals' ZEVALIN (ibritumomab tiuxetan) for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.
The industry has witnessed significant strategic movements throughout 2023-2024, highlighting the growing importance of radioligand therapies in oncology portfolios. In March 2024, AstraZeneca (LON: AZN) acquired Fusion Pharmaceuticals (NASDAQ: FUSN) for USD 2 billion to accelerate the development of next-generation radioconjugates, bringing new expertise and pioneering R&D in actinium-based radioconjugates to enhance their cancer treatment pipeline. Furthermore, in May 2024, Novartis acquired Mariana Oncology, a cancer RLT-focused biotech, for USD 1 billion upfront with potential additional payments of up to USD 750 million upon milestone completion.
In December 2023, Eli Lilly completed its acquisition of Point Biopharma for approximately USD 1.4 billion, gaining ownership of Point's lead asset PNT2002, a radioligand therapy targeting PSMA for metastatic castration-resistant prostate cancer. Additionally, January 2024 saw two significant operational developments: the FDA's approval of Novartis's new automated radioligand therapy production plant for PLUVICTO, and InHealth's launch of the UK's first relocatable radioligand therapy service, enhancing treatment accessibility.
Discover evolving trends in the radioligand therapies landscape @ Radioligand Therapies Recent Developments [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The radioligand therapy pipeline continues to expand with several promising candidates advancing through clinical development. Curium US (NASDAQ: CURI) is developing 177Lu-PSMA-I&T, currently in phase III ECLIPSE trial (NCT05146973), which targets prostate-specific membrane antigen. Eli Lilly (NYSE: LLY) and Point Biopharma (NASDAQ: PNT) are advancing Lu-PNT2002, a PSMA-targeted lutetium-177-based radioligand therapy currently in phase III SPLASH trial (NCT04647526) combines PSMA-I&T with the beta-emitting radioisotope no-carrier-added lutetium-177.
Other pipeline candidates include Fusion Pharmaceuticals' FPI-2265 in Phase II/III studies, Lantheus (NASDAQ: LNTH) and Eli Lilly's LNTH-1095, Novartis's 225Ac-PSMA-R2, and Bayer's 225Ac-PSMATrillium, all targeting various stages of prostate cancer and poised to expand treatment options in the coming years.
The market's growth trajectory is supported by increasing cancer diagnosis rates, growing awareness of radioligand therapy's benefits, expanding clinical trial activity, and major pharmaceutical companies' increasing interest in this therapeutic space. With Novartis already having two RLTs available globally, numerous candidates in its pipeline, and several clinical trials underway or planned, the radioligand therapy market is positioned for sustained expansion.
Download the Radioligand Therapy Market Forecast Report to understand which factors are driving the Radioligand Therapy market @ Radioligand Therapy Market Trends [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
As more data becomes available from ongoing clinical trials and new applications are discovered for conditions beyond the current indications of neuroendocrine tumors and prostate cancer, radioligand therapy is expected to become an increasingly integral component of cancer treatment protocols, further driving market growth and improving outcomes for patients with difficult-to-treat malignancies across the 7MM.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Radioligand Therapies
4. Key Events
5. Radioligand Therapies Market Overview At A Glance
6. Background And Overview
7. Target Population
8. Radioligand Therapies Marketed Drugs
9. Radioligand Therapies Emerging Drugs
10. Radioligand Therapies: The 7MM Analysis
11. Radioligand Therapy Unmet Needs
12. SWOT Analysis
13. KOL Views
14. Radioligand Therapy Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=novartis-radioligand-therapies-pipeline-and-strategic-acquisitions-key-drivers-behind-radioligand-therapies-market-exponential-growth-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novartis' Radioligand Therapies Pipeline and Strategic Acquisitions: Key Drivers Behind Radioligand Therapies Market Exponential Growth Through 2034 | DelveInsight here
News-ID: 4019190 • Views: …
More Releases from ABNewswire
Lawrence Paulraj Announces the Release of His Debut Book, Building Things That L …
Lawrence Paulraj, Founder and CEO of LP Construction Group, has officially announced the upcoming release of his debut book, Building Things That Last. Set to launch at the end of 2025, the book is a great resource for individuals seeking to live with greater purpose and clarity of vision.
Written from decades of personal and professional experience, Building Things That Last explores the essential role that vision plays in life. With…
Jesus Empire Launches 4G/5G Mobile Proxies to Empower Safe, U.S.-Sourced Social …
Real rotating 4G/5G LTE IPs (U.S. only) for safer multi-account management, geo-targeting, and automated engagement
Jesus Empire today announced the launch of Jesus Empire 4G/5G Mobile Proxies [https://jesusempire.com/jesus-empire-5g-mobile-proxies/], a next-generation proxy service providing real rotating U.S.-sourced 4G and 5G LTE IP addresses for creators, marketers, and automation agencies. By delivering genuine mobile IPs from U.S. carriers, Jesus Empire's proxies help clients scale social media campaigns with enhanced account safety, reduced ban…
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill …
Antibiotic resistance has become one of medicine's most urgent challenges. The CDC estimates that resistant infections cause ~35,000 deaths each year in the U.S. and more than 1 million globally - a number projected to rise sharply over the next 25 years. Traditional drug development is struggling to keep pace, forcing healthcare systems to look beyond antibiotics altogether.
That search has reignited interest in a century-old idea that suddenly looks like…
Dermis Advanced Skin Care Introduces Cutting-Edge HydraFacial Technology to Otta …
Dermis Advanced Skin Care introduces cutting-edge HydraFacial technology to Ottawa's medical skin care clinic landscape. The non-invasive treatment delivers deep cleansing, exfoliation, and hydration for instantly radiant skin. Suitable for all skin types, HydraFacial reflects Dermis' commitment to innovation and excellence in advanced aesthetic care.
Ottawa, ON - October 27, 2025 - The growing demand for non-invasive facial rejuvenation continues to shape Ottawa's medical aesthetics scene, as Dermis Advanced Skin Care,…
More Releases for Radioligand
Radioligand Therapies Pipeline: Strategic Acquisitions, Key Drivers | DelveInsig …
The radioligand therapies market is experiencing remarkable expansion, with significant growth projected through 2034. Novartis has emerged as the market leader in this landscape, with PLUVICTO and LUTATHERA capturing the largest market share.
DelveInsight's report, "Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 [https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides in-depth analysis of radioligand therapies market dynamics, epidemiology trends, and emerging technologies that will shape the future of radioligand therapies, which…
Radioligand Therapy Market Research Report 2025-2031
Catalyst Introduction
The Radioligand Therapy Market Research Report 2025-2031 by Market Research Corridor is a catalyst for innovation in the global Radioligand Therapy market. Designed for trailblazers, this report ignites strategic thinking with in-depth analysis of market trends, technologies, regulations, and competition, forecasting through 2031. With over 100 data tables, charts, and visuals, it sparks transformative ideas for market leadership.
Ignite your strategy with a free sample: https://marketresearchcorridor.com/request-sample/15502/
Innovation Sparks
Market Igniters
Fuel your strategy…
Radioligand Therapy Market Study Analysis with Forecast to 2034
The Radioligand Therapy Market Size is valued at USD 2.31 Billion in 2024 and is predicted to reach USD 8.33 Billion by the year 2034 at a 12.1% CAGR during the forecast period for 2025-2034.
Global Radioligand Therapy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1281
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Radioligand Therapy market…
Radioligand Therapy Market is on an Upward Growth Curve
The Radioligand Therapy Market Size is valued at USD 1.8 Billion in 2023 and is predicted to reach USD 2.8 Billion by the year 2031 at a 5.60% CAGR during the forecast period for 2024-2031.
Global Radioligand Therapy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1281
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Radioligand Therapy market…
Radioligand Therapy Market Was Dominated by United States
The total size of the radioligand therapy market was USD 7,785.6 million in 2021, and powering at a rate of 5.9% during the coming years, it will reach USD 13,073.9 million by 2030, as stated in one of its reports by P&S Intelligence.
Browse full report at: https://www.psmarketresearch.com/market-analysis/radioligand-therapy-market
The advances in nuclear medicine will be the main enabler for radiopharmaceuticals to get a major place in medicine. These are being progressively used…
Radioligand Therapy Market To Reach $13,073.9 Million by 2030
The major drivers in the global radioligand therapy market are skyrocketing demand for highly efficient drugs and surging investments in research and development of cancer treatment. In 2021, the market was valued at $7,785.6 million, and it is predicted to touch $13,073.9 million by 2030. Moreover, the market will witness an approximately 6% CAGR from 2021 to 2030. Additionally, this market had witnessed magnificent growth in the count of FDA-approved…
